Articles tagged with Clinical Studies
The first patient has been enrolled in a global Phase 3 clinical trial evaluating Mocertatug Rezetecan, a novel B7-H4-targeted ADC, in platinum-resistant ovarian cancer. The study aims to determine whether this therapy can improve outcomes compared with standard chemotherapy.
Exercise produces small improvements in pain and physical function for people with hip osteoarthritis, but those improvements may not be large enough to make a meaningful difference in daily life. Quality of life showed little to no improvement with exercise.
The Biggs Institute is leading a $2.5 million national, multi-site study to improve detection and diagnosis of dementia with Lewy bodies. The study will enroll 125 participants and evaluate multiple possible new tools and methods to accurately identify individuals who have accumulated abnormal alpha-synuclein in the brain.
A new cancer drug has shown promising results in a mesothelioma trial, controlling disease progression in 67% of patients. The drug targets the cancer's energy system by inhibiting a specific enzyme, causing oxidative stress that kills tumor cells.
A new study found that simple weekly electronic symptom check-ins with care teams significantly improves the quality of life for individuals undergoing treatment for advanced cancer. The benefits were notable among patient groups that historically faced barriers to care, including Black patients and those with less formal education.
A landmark study has shown that transplanting stem-cell derived dopamine progenitor cells into the brain is feasible and safe. Eight patients received the transplanted cell product, with no serious side effects observed during the first year of follow-up.
A randomized clinical trial found that acupuncture to the ear (auriculotherapy) reduced migraine pain and improved its impact on daily life. The treatment showed a statistically significant improvement in oxygenation levels in the brain, but not a difference between the auriculotherapy and sham groups.
The University of California, San Francisco is launching a novel clinical trial to test a combination of therapies for the most common form of Alzheimer's disease. The trial will enroll up to 825 participants and test drugs that target both amyloid and tau proteins, with the goal of slowing disease progression.
Rentosertib is a potentially first-in-class oral small-molecule inhibitor targeting TNIK for the treatment of idiopathic pulmonary fibrosis. The Phase III clinical trial will evaluate the efficacy and safety of once-daily Rentosertib administered over 52 weeks.
The FDA has granted early access to clinical trials for the new medication, allowing HonorHealth Research Institute to offer it to patients with previously treated metastatic pancreatic cancer. The drug has shown significant advancement in targeted therapy for pancreatic cancer, offering a median overall survival of 13.2 months.
Researchers will study blood samples and environmental exposures over 10 years to identify genetic, environmental, and cellular factors contributing to autoimmune diseases. The goal is to develop prevention strategies and treatments by understanding the earliest biological triggers of SARDs.
A large clinical trial found that an AI support tool improved the quality of clinical documentation and treatment planning, but did not significantly change short-term patient outcomes. The study involved over 9,600 patients in Kenya and used a randomized controlled design to test the effectiveness of the AI tool.
A new study suggests that functional brain imaging can help guide accelerated transcranial magnetic stimulation (TMS) for depression, leading to improved symptoms and response rates. The approach uses resting-state functional connectivity analysis to identify individualized treatment targets.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers at UCI Health have begun the world's first clinical trial for Huntington’s disease using neural stem cells. The phase 1b/2a trial aims to evaluate the safety and potential benefits of this innovative therapy, which could slow disease progression and reduce long-term care costs.
Researchers discovered Paneth cell metaplasia can act as a protective response in ulcerative colitis by promoting healing and regeneration of the intestinal lining through REG3A. However, persistent changes may still carry risks, including increased cancer risk.
The FDA has accepted Genentech's supplemental Biologic License Application for atezolizumab, supported by phase III ATOMIC trial results. The trial showed a 50% reduction in cancer recurrence or death and 86.3% disease-free survival rate.
A clinical trial tested four remote monitoring approaches against usual care and found that none outperformed usual care in reducing readmissions. The study highlights the importance of studying real-world care models to optimize outcomes.
A multinational clinical trial found that balanced crystalloid fluid and 0.9% saline are equally safe and effective for treating septic shock in children. The study enrolled over 9,000 children and showed no difference in outcomes between the two IV fluids.
Dr. Nageatte Ibrahim brings her expertise in immunotherapy and cancer drug development to HonorHealth Research Institute, focusing on advancing novel treatments and improving patient outcomes. The institute aims to develop collaborations with leading research centers worldwide to bring cutting-edge therapies to patients in need.
The FLOW trial shows that semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease. Health utility scores and self-rated general health scores improved with semaglutide, but declined with placebo.
The FUTURE-D project combines data science with clinical expertise to identify warning signs of depression earlier, enabling more targeted interventions. Researchers will integrate longitudinal cohort data from the MACS and NESDA studies to better understand depressive disorders.
Dr. Mina Sedrak has been selected to co-lead the Cancer in the Older Adult Committee of The Alliance for Clinical Trials in Oncology, focusing on improving care and outcomes for older adults with cancer. As a leading expert on aging and cancer, Sedrak aims to expand research on this population and address their unique needs.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
A nationwide study has compared two surgical approaches for treating Chiari malformation and syringomyelia, finding no difference in complication rates and clinical outcomes. Patients who underwent the more invasive procedure had greater improvement in their syringomyelia symptoms.
The UMass Center for Clinical and Translational Science has received a seven-year, $50 million grant from the NIH. The funding supports collaboration among researchers at multiple UMass campuses and clinical partners.
The Restore-1 clinical trial aims to modify the small intestine's lining with steam energy to restore natural blood-sugar control in patients with type 2 diabetes. The procedure, if successful, could prevent patients from advancing to insulin-dependent diabetes.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
A new Cochrane review finds planned early birth for pregnant women with high blood pressure cuts maternal complications by nearly half and reduces the risk of stillbirth. The practice is found to be safe across both high- and low-income settings, without increasing the likelihood of caesarean section.
Researchers found that stereotactic body radiotherapy (SBRT) improved progression-free survival by 15.6 months, compared to 20.6 months without targeted therapy. The treatment also showed no significant impact on quality-of-life measures.
A novel antibody, NG101, accelerates the regeneration of damaged spinal cord tissue by neutralizing a protein that blocks nerve fiber growth. This therapy enables new nerve fibers to form functional connections, allowing patients to become more independent and potentially recover arm and hand function.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A new study published in Eye and Vision finds that one drop of low-dose atropine can produce daylong effects in managing myopia. The researchers found that the drop showed clear changes in pupil size and focusing ability, but no short-term structural effects on the eye.
The Patient-Centered Outcomes Research Institute (PCORI) has awarded funding for new patient-centered comparative clinical effectiveness research projects. These studies will examine different approaches to care across various health concerns, aiming to generate evidence for patients to make informed choices.
A new review proposes a prevention-focused framework for understanding Parkinson's disease risk, highlighting the role of early-life vulnerability, environmental exposures, and resilience factors. The study suggests that susceptibility to PD may begin earlier in life through interactions between biology and environment.
Researchers agree on core elements of ACLF development, including chronic liver disease triggers, acute insult, and extrahepatic organ failure. A new three-stage mouse model supports testing of potential therapies, highlighting impaired liver regeneration as a key driver of disease progression.
Researchers found three distinct trajectories of cognitive decline: stable, slow and fast decline. Biomarker data showed that participants who declined faster had higher P-tau217 levels and smaller hippocampi.
A new study reveals that over 75% of older adults have used complementary health approaches, including mindfulness, yoga, tai chi, acupuncture, and more. The study highlights the need for healthcare providers to discuss the risks and benefits of these therapies with their patients.
A new study suggests that a low dose of ibuprofen can help alleviate chemo-brain symptoms in cancer patients, but exercise remains the most beneficial intervention. Researchers randomized 86 patients to receive either exercise plus ibuprofen or other treatments and found that exercise significantly improved cognitive function.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
A first-in-human trial shows that an infusion of immune cells derived from a donor's blood can prime the recipient's immune system to accept a donor liver, potentially reducing lifelong immunosuppression. Eight out of 13 participants achieved complete withdrawal of immunosuppression and remained off for more than three years.
A clinical trial has shown that stent placement can effectively treat post-thrombotic syndrome, a common complication of deep vein thrombosis. The study found significant improvements in venous symptoms and overall quality of life for patients who received the procedure.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
A new clinical trial at the University of Cincinnati is testing a peptide solution to treat prosthetic joint infections after total knee replacement. The trial aims to reduce the need for repeat surgeries and expand the treatment window beyond two weeks.
Nancy L. Lewis, MD, MBS, FACP, a renowned biomedical researcher and clinical trials expert, has been appointed as the new Chief Scientific Officer of the National Comprehensive Cancer Network (NCCN). She will oversee NCCN's programs to advance clinical trials and improve cancer care outcomes globally.
Researchers compare viral and MASLD cirrhosis pathogenic mechanisms, identifying shared pathways and diagnostic differences. The study aims to establish a framework for prevention, diagnosis, treatment, and monitoring of MASLD cirrhosis.
The S2419 BioFront study aims to enroll over 700 patients with advanced renal cell carcinoma and test the safety and efficacy of a CBM588 capsule as part of an immunotherapy-based treatment. The trial seeks to improve outcomes for patients by leveraging the gut microbiome.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
OYE-101, a novel intravenous caffeine formulation, has been developed to accelerate recovery from general anesthesia and deep sedation. The company's lead program is being evaluated in a scientific bridging study to support a 505(b)(2) NDA for OYE-101.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
A multicenter analysis of 920 patients with compensated cirrhosis found that interferon therapy was not associated with a higher risk of serious complications compared to standard treatment. Milder side effects were more common and required closer monitoring.
The review highlights LRRK2's diverse cellular functions and pathogenic mechanisms in various diseases, including Parkinson's disease and inflammatory disorders. Therapeutic strategies targeting LRRK2, such as kinase inhibitors and emerging approaches like PROTACs and gene therapy, show promise for correcting cellular imbalances and re...
The Robert A. Winn Excellence in Clinical Trials Award Program has partnered with AstraZeneca to support five medical students participating in the Winn Clinical Investigator Pathway Program (Winn CIPP). The program provides immersive training, mentorship, and hands-on experience to prepare students for careers in clinical research.
A multicenter study found that red blood cell exchange transfusion significantly improves clinical outcomes for patients hospitalized with severe babesiosis, a potentially life-threatening tick-borne infection. The procedure was associated with substantially lower risk of in-hospital death or readmission.